echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Shanghai Hutchison Pharmaceuticals was selected as "Top 100 Chinese Patent Medicine Companies" and Shexiang Baoxin Pills were listed on "2021 Clinical Value Chinese Patent Medicine Brand List"

    Shanghai Hutchison Pharmaceuticals was selected as "Top 100 Chinese Patent Medicine Companies" and Shexiang Baoxin Pills were listed on "2021 Clinical Value Chinese Patent Medicine Brand List"

    • Last Update: 2022-01-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    <> /* Style Definitions */ span.
    prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
    prnews_a { color:blue; } li.
    prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.
    prnews_p { font-size:0.
    62em; font-family:"Arial"; color:black; margin:0in; }

    Shanghai, December 23, 2021/PRNewswire/ - Recently, at the Chinese Medicine Industry Information Conference of China Association of Chinese Medicines, the "2021 Top 100 Chinese Patent Medicine Companies" and "2021 Clinical Value Chinese Patent Medicine Brand List" lists were released
    Shanghai Hutchison Pharmaceuticals was selected as the "Top 100 Chinese Patent Medicine Companies", and Shexiang Baoxin Pills were listed in the "2021 Clinical Value Chinese Patent Medicine Brand List"


    In recent years, with the great attention and policy support of the Party Central Committee and the State Council, the development momentum of the Chinese medicine industry has been strong
    In order to shape the brand image, enhance the overall competitiveness of Chinese medicine companies, and promote the high-quality development of the Chinese medicine industry, the China Association of Chinese Medicines has launched the selection of clinical value Chinese patent medicine brands and TOP100 Chinese patent medicine companies

    The brand list is based on the standards and procedures of the traditional Chinese medicine brand evaluation group, through literature search, corporate product information solicitation and brand expert group active research, adhere to the one-vote veto principle of negative information, and conduct multiple rounds of discussion and evaluation


    Shanghai Hutchison Pharmaceuticals has 74 products, including pills, tablets, injections and other dosage forms, the registered trademark of "Shangyao", and a series of modern Chinese medicine products such as Shexiang Baoxin Pills, Danning Tablets, and Shengmai Injection
    On the basis of inheriting classic traditional Chinese medicine products, relying on Hutchison Whampoa’s strong technical research and development capabilities, the company has invested a lot of money, continuously applied international advanced science and technology and methods to carry out secondary development of traditional Chinese medicine products, and further clarified the medicine of compound Chinese medicine.
    Effective material basis, mechanism of action and clinical efficacy, a comprehensive quality control system for modern Chinese medicine has been established, and intellectual property protection has been strengthened, creating a new situation for the modernization and internationalization of Chinese medicine in China


    Shexiang Baoxin Pills originated from the famous prescription Suhexiang Pills in the Song Dynasty.
    It was marketed in 1981.
    It is a classic Chinese patent medicine for the treatment of coronary heart disease and angina pectoris

    Its modern innovation research results have successively won the "2011 Shanghai Municipal Science and Technology Progress Award" and the "2018 National Science and Technology Progress Award".
    More than 2,800 papers and more than 80 SCI papers have been published in authoritative magazines at home and abroad.
    One of the successful representatives of the modernization research of Chinese traditional medicine and the secondary development of large varieties of traditional Chinese medicine


    In 2020, the results of a large-scale evidence-based study of Shexiang Baoxin Pills, led by academician of the Chinese Academy of Sciences, Professor Ge Junbo of Zhongshan Hospital Affiliated to Fudan University, and Professor Fan Weihu of Huashan Hospital Affiliated to Fudan University, in line with international standards, were published in the Chinese Medical Journal.
    Edition", CMJ for short) was officially published

    As one of the few multi-center, randomized, double-blind, placebo-controlled phase IV clinical trials in China's traditional Chinese medicine research, it can be called a landmark study in the modernization of traditional Chinese medicine and has important clinical guidance value for the treatment of coronary heart disease


    Danning tablets, another key product of the company, obtained the Canadian natural medicine marketing license and the certification of production sites outside Canada in 2016 and 2019 respectively, becoming one of the successful models of the internationalization of traditional Chinese medicine

    Shanghai Hutchison Pharmaceuticals adheres to the mission of "innovating traditional Chinese medicines and serving healthy China", and continuously promotes the modernization and internationalization of Chinese medicines
    In 2017, the company's academician expert workstation was awarded the "National Demonstration Academician Expert Workstation"; in 2019, the company's enterprise technology center was awarded the "National Enterprise Technology Center"; in 2021, the company was awarded the "National Technological Innovation Demonstration Enterprise"

    In addition, the company has won many honors such as the Top 100 Chinese Pharmaceutical Manufacturing Enterprises, the Most Growing Enterprise in China's Pharmaceutical Industry, and the Most Technologically Innovative Chinese Medicine Enterprise

    In the future, Shanghai Hutchison Pharmaceuticals will adhere to integrity and innovation, continue to move forward on the path of inheritance and development of Chinese medicine, and write new chapters


    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.